Inimmune focuses on harnessing the immune system to improve human health, self-described as involved in various immunotherapies.

Inimmune

Viewport Meta

IPhone / Mobile Compatible

Google Font API

Google Maps

WordPress

Font Awesome

Organization Schema

Person Schema

Gravatar Profiles

GStatic Google Static Content

Chief Executive Officer

Alan Joslyn

Chief Operating Officer

David Burkhart

Healthcare

Jon Ruckle

Formulations Development Manager

Eric Ward

HR and Administrative Lead

Marie Snyder

Research Associate Scientist

Alec Cottrell

Immunologist

Caleb Beyer

Research Associate

Cherrokee Sands

Chief Scientific and Strategy Officer

Evans Jay

Engineering

Janine (Hall) Ward

Mike Goguen

David J. Burkhart

Co-Founder & Chief Operating Officer

Helene Bazin-Lee

Co-Founder & Vice President Early Discovery

Jay T. Evans

President & CEO

Kendal Ryter

VP Product Development

Biotechnology Companies With Fewer Than 1000 Employees (Top 10K)

Western US Health Care Female Founded Companies

Montana Health Care Companies

Western US Female Founded Companies (Top 10K)

Inimmune is focused on the discovery and development of novel immunotherapeutics for an array of disease areas.

Inimmune technology is focused on the discovery, optimization, and development of new innate immune receptor agonists and antagonists to treat a wide array of medical conditions including allergy, autoimmune diseases, and cancer.

It was founded in 2016 and based in Missoula, Montana.

Two Bear Capital

Series A - Inimmune

National Institute of Allergy and Infectious Diseases

Grant - Inimmune

Missoula

Montana

United States

North America

Inimmune publishes positive proof of mechanism for TLR4 Agonist INI-2004 in Allergic Rhinitis

INIMMUNE ANNOUNCES FIRST CANCER PATIENT DOSED IN PHASE 1 CLINICAL STUDY USING THE IMMUNOTHERAPEUTIC INI-4001, A NOVEL TLR7/8 AGONIST

SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems

INIMMUNE ANNOUNCES SUCCESSFUL PHASE 1 CLINICAL RESULTS FOR DISEASE MODIFYING ALLERGY ...

Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy

Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long ...

UM Researchers Prep Fentanyl, Heroin Vaccines for Human ...

Inimmune's new CEO Alan Joslyn takes the helm

Inimmune Raises $22M in Series A Funding

Turkmenistan

Asia

Chile

South America

India

France

Europe

Colombia

HTML5

Office 365

Google Analytics

Apache Server

Vimeo

Google Fonts

Microsoft Outlook

Bootstrap

jQuery

F5 NGINX

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 13, 2024 8:56 AM	69bc5891
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 13, 2024 8:56 AM	1d7dbed0
crunchbase trigger	general	Nov 4, 2024 10:53 AM	108323e0
crunchbase profile	general	Nov 4, 2024 1:40 PM	d7f9a11c
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	32aebb54
peers	general	Sep 13, 2024 8:56 AM	f8b7e4af
news basic	general	Sep 13, 2024 8:56 AM	07769195
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:INIMMUNE

Inimmune